Physician profile
Alexandra Grace
NPI 1861773533
$10,723.43
in general payments reported to CMS, 2019-2025
38 companies · $2,276 in 2025
The $2,276 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $403 · 2021: $587 · 2022: $1,833 · 2023: $2,398 · 2024: $2,600 · 2025: $2,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,174 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,174.41 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,904.18 | 2019-2025 | |
| Janssen Biotech, INC. | $909.74 | 2020-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $902.07 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $874.50 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $671.09 | 2019-2025 | Epclusa |
| Boston Scientific Corporation | $633.46 | 2019-2025 | Exalt Model D, Axonics, Compliance Endokit |
| Phathom Pharmaceuticals, INC. | $586.83 | 2023-2025 | Voquezna |
| Axonics, INC. | $576.85 | 2022-2024 | Axonics |
| Madrigal Pharmaceuticals | $473.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $344.86 | 2021-2024 | Zeposia |
| Pfizer INC. | $285.80 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $206.26 | 2024 | |
| Intercept Pharmaceuticals, INC. | $162.59 | 2022-2024 | |
| Vivus LLC | $141.26 | 2023-2025 | Pancreaze, Qsymia |
| Mauna Kea Technologies, INC. | $139.64 | 2023-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Grace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.